- Click to readA Woman's 'Untreatable' TB Echoes Around the World - WSJ.com
- Click to readIndia steps up TB fight as fears of drug-resistant strains mount
- Click to read1st Indian in the country to have a lung transplant is Dr Udwadia's patient
- Click to readWSJ: India in Race to Contain Untreatable Tuberculosis
- Click to readThe Times of India: Soon, breath test to tell tuberculosis in just 6 minutes
- Click to readThe Times of India: National Tuberculosis Institute validates Hinduja Hospital's report that 8 infected people are fully drug resistant
- Click to readTB institute confirms 8 patients resistant to all known TB drugs
- Click to readNew, deadlier form of TB hits India - Times of India
- Click to readErratic TB medication led to absolute resistance: Docs - Hindustan Times
- Click to readFirst cases of totally drug resistant TB in India, one dead - DNA
- Click to readMumbai hospital reports first set of ‘total’ drug-resistant TB cases - Indian Express
- Article from 'The Independent' :
- Drug-resistant TB complicates India's health drive
- click to view
- Highest number of TB cases
- Click to readwww.hindujahospital.com
- Click to readPubMed
- Dr Zarir Udwadia's website created by
- Plus91 Technologies
Welcome to Dr Zarir F Udwadia's Website
Dr Zarir F Udwadia is a consultant chest physician at the Hinduja Hospital, Breach Candy Hospital and Parsee General Hospitals. He is an MD, DNB, FRCP (London.), and FCCP (USA). A post-graduate of the Grant Medical College, Bombay, he has spent 5 years training in various centers of excellence in the U.K including the prestigious Brompton Hospital, London. On his return he established an active chest department at the Hinduja Hospital. This includes Bombay's busiest bronchoscopy and PFT services and the city's first sleep laboratory. More
Special Mention
A) The only Indian doctor to be invited by WHO, Geneva to be part of a core task force to formulate new TB treatment guidelines for 2009 at a meeting held in Paris in 2008 October.
B) Dr Zarir Udwadia and team are the first to describe Totally Drug Resistant TB (TDR-TB) from India. This attracts intense media and scientific attention with coverage by all the National dailies and BBC, Science, Nature, Wall Street Journal, CNN, and Lancet coverage.
Photographer: Lauren Rudser
Articles by Dr Udwadia
1. Totally drug resistant tuberculosis in India. Clinical Infectious Diseases. 2012;54:579-581.
2. Prevalence of venous thromboembolism in acute exacerbations of chronic obstructive pulmonary disease: an Indian perspective. Indian J Chest Dis Allied Sci 2011:53(4): 207-210.
3. Primary immune deficiency in the intensive care unit: it's never too late to diagnose and treat. Indian J Crit Care Med. 2011:15(3): 179-181.
4. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discovery. 2011:6(2): 88-91.
1. Private patient perceptions about a public programme: what do private Indian tuberculosis patients really feel about directly observed treatment? BMC Public Health. 2010 Jun 22; 10(1): 357.
2. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades. PLoS ONE Aug 2010. Vol 5: Issue 8: e12023
3. Tumor necrosis alpha-blocker induced tuberculosis. J Rheumatol 2010: 37::7: 1542.
4. Evaluation of light emitting diode-based fluorescence microscopy for the detection of mycobacteria in a tuberculosis-endemic region. Int J Tuberc Lung Dis 2011. 15(4): 483-488.
5. Universal access for MDR-TB limited without the involvement of the private sector. Int J Tuberc Lung Dis. 2011
6. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discovery. 2011. 1:6; (2): 88-91.
7. Retrospective study of ILD in a tertiary care center in India. Indian J Chest Disease Allied Science. 2010; 52: 191-193.
8. Why 'STOP TB' is incomplete without quit smoking. Indian J Chest Dis Allied Sci. 2011; 53: 9-10.
9. Statins and the lung: hope or hype? Indian J Chest Dis Allied Sci. 2011
10. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.
Click to view more articles by Dr Udwadia
